Evidence map›Paper›PMID 30191122›Full record

ArticleRespiratory medicine case reports2018

Elham Karamooz, Vanessa L Yap, Alan F Barker, Mark L Metersky

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Usefulness of business intelligence to guide antimicrobial treatment decision in infections by infrequent microorganism such asRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Article
  2. Persistent microbial infections and idiopathic pulmonary fibrosis - an insight intoFrontiers in cellular and infection microbiology · 2024
    Review
  3. IDCases · 2022
    Article
  4. Conquering the host:Frontiers in microbiology · 2022
    Review
  5. Co-infection of SARS-CoV-2 andRespiratory medicine case reports · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Elham KaramoozDivision of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR 97239, USA.
Vanessa L YapDivision of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut, Farmington, CT 06030, USA.
Alan F BarkerDivision of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR 97239, USA.
Mark L MeterskyDivision of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut, Farmington, CT 06030, USA.
Oregon Health & Science University · USUniversity of Connecticut · US

Funding

Multidisciplinary Research Training in Pulmonary MedicineT32HL083808 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., SLATORE, CHRISTOPHER G. · 2008 to 2025
$5.3M
NHLBI NIH HHS T32 HL083808
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bordetella bronchisepticaBronchiectasisCF, cystic fibrosisCOPD, chronic obstructive pulmonary diseaseMicrobiology

Identifiers

PMID30191122
PMCPMC6125826
OpenAlexW2889524692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.